A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

This study tests whether combining a new drug called SKB264 (an antibody-drug conjugate that targets TROP2) with osimertinib (a standard EGFR-targeted therapy) works better than osimertinib alone as a first-line treatment for people with advanced non-squamous non-small cell lung cancer that has a sensitive EGFR mutation. **You may be eligible if...** - You are 18–75 years old with advanced or metastatic non-squamous NSCLC - Your tumor has a confirmed EGFR-sensitive mutation - You have not received any prior systemic treatment for advanced NSCLC - You are in good health (ECOG 0–1) with adequate organ function and a life expectancy of at least 12 weeks **You may NOT be eligible if...** - You have received prior EGFR therapy, TROP2-targeted therapy, or topoisomerase I inhibitors - You have active or symptomatic brain metastases, spinal cord compression, or meningeal involvement - You have interstitial lung disease, heart disease, or significant cardiovascular risk factors - You have had another cancer within 3 years - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.